Welcome to our dedicated page for Mesa Laboratories SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mesa Laboratories SEC filings document the company's life sciences tools and critical quality control business, its Nasdaq-listed common stock and formal disclosures around operating results, governance and capital structure. Form 8-K reports furnish quarterly financial releases, record annual meeting voting outcomes and report executive succession, director changes and related compensation arrangements.
Other filings and exhibits describe the company's credit facility borrowings, convertible note settlement funding, independent auditor ratification, board committee structure and proxy compensation disclosures. These records frame Mesa's disclosure obligations across its four operating divisions and its financing, shareholder-vote and leadership-transition matters.
Mesa Laboratories outlines its business, strategy and risks as a global provider of life sciences tools and quality-control solutions serving pharmaceutical, healthcare and medical device markets. The company operates four divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions and Clinical Genomics.
Mesa highlights its lean-based "Mesa Way" operating system, focus on recurring consumables revenue and global manufacturing footprint in the U.S. and Europe. It reports a GKE acquisition for $87,187 (net of cash and liabilities) to expand sterilization indicators, and backlog of $33.6 million as of March 31, 2026 versus $43.2 million a year earlier, mainly from timing in Clinical Genomics and normalized sterilization orders.
The filing details diversified customers, with no single customer above 10% of consolidated revenue, though one Clinical Genomics customer represents about 20% of that division’s revenue. Mesa also discloses 717 employees, reliance on key talent, and extensive risk factors spanning macro conditions, international operations, supply chain, regulation, cybersecurity, climate, tariffs and a planned CEO transition effective April 2026.
Mesa Laboratories reported modest growth for its fourth quarter and full fiscal year 2026 ended March 31, 2026. Quarterly revenues were $63,724, up 2.6% year over year, with strong Sterilization and Disinfection Control growth offset by a sharp decline in Biopharmaceutical Development.
For FY26, revenues reached $249,130, a 3.4% increase, while net income improved to $6,712, or $1.21 per diluted share, compared with a prior-year loss. Non-GAAP adjusted operating income excluding unusual items rose 11.9% to $63,487, representing a 25.5% margin. Free cash flow was $39,581, allowing the company to reduce its Total Net Leverage Ratio to 2.11.
Mesa Laboratories President and CEO Siddhartha Kadia received a grant of restricted stock units that can convert into 35,236 shares of common stock. The award was recorded at a price of $0.00 per unit as a stock-based compensation grant. Each RSU represents a right to receive one share of common stock and is scheduled to vest in three equal installments, with one-third vesting on each anniversary date of the grant. Following this award, Kadia is reported as directly holding 35,236 RSUs tied to common stock.
Kadia Siddhartha reported acquisition or exercise transactions in this Form 4 filing.
Mesa Laboratories reported that President and CEO Siddhartha Kadia received a grant of 34,807 Restricted Stock Units (RSUs) linked to the company’s common stock. Each RSU represents a contingent right to receive one share of common stock.
The RSUs vest in thirds, with 1/3 of the award vesting on each anniversary date, aligning the CEO’s compensation with longer-term company performance. Following this grant, the filing shows 34,807 RSUs held directly by the CEO, and no remaining derivative positions are listed in this report.
Mesa Laboratories President and CEO Siddhartha Kadia has filed a Form 3 insider report. The filing lists him as an officer but shows no reported purchases, sales, gifts, tax withholdings, or derivative transactions, indicating there are currently no insider trades or holdings disclosed in this report.
Long Path funds and affiliated managers amend a Schedule 13G to report ownership of 405,583 shares of Mesa Laboratories, Inc. Common Stock, equal to 7.3% of the class. Percentage is based on 5,524,813 shares outstanding as of January 31, 2026. The shares are directly held by Long Path Smaller Companies Fund, LP; the Reporting Persons disclaim beneficial ownership except to the extent of their pecuniary interest. This filing is Amendment No. 1 to the previously filed Schedule 13G.
Mesa Laboratories President and CEO Gary M. Owens reported the expiration and forfeiture of 8,211 restricted stock units, each representing one share of common stock. The RSUs were due to vest on June 15, 2028, but were deemed expired on March 31, 2026 and returned to the issuer rather than sold on the market. Following this disposition to the company, Owens holds 16,448 restricted stock units directly.
Mesa Laboratories Inc — Schedule 13G/A (Amendment No. 6) by The Vanguard Group. The filing states that The Vanguard Group reports zero shares beneficially owned of Mesa Laboratories common stock and 0% of the class. The amendment explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries or divisions to report separately and disaggregated from The Vanguard Group, Inc. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Mesa Laboratories detailed the transition of President and CEO Gary Owens, whose departure was previously announced and will be effective on or about April 13, 2026. Under a new Retention and Transition Agreement dated March 20, 2026, he will continue in a non-executive role until June 22, 2026 to support an orderly handover.
At his June 22, 2026 separation, Mr. Owens will receive severance pay and benefits consistent with a “without cause” termination and keep a pro-rated portion of his June 15, 2025 performance stock unit award, vesting at the lower of target or actual performance. He must sign a release of claims to receive these benefits. He also resigned from the board as of March 20, 2026, and the company states his resignation was not due to any disagreement over operations, policies, or practices.
Mesa Laboratories (Common Stock) Schedule 13G: Long Path-related reporting persons report beneficial ownership of 311,703 shares, representing 5.6% of the class. Percentage ownership is based on 5,524,813 shares outstanding as of January 31, 2026.
The filing lists the owner as Long Path Smaller Companies Fund, LP with affiliated entities and two co-portfolio managers joining a joint filing. The shares are directly held by the Fund and the reporting parties disclaim beneficial ownership except for pecuniary interest.